IL6 elevation
|
Melanoma
|
IL6 elevation
|
Melanoma
|
ipilimumab Resistant: B - Late Trials
|
ipilimumab Resistant: B - Late Trials
|
IL6 elevation
|
Melanoma
|
IL6 elevation
|
Melanoma
|
nivolumab + ipilimumab Resistant: B - Late Trials
|
nivolumab + ipilimumab Resistant: B - Late Trials
|
IL6 elevation
|
Gastric Cancer
|
IL6 elevation
|
Gastric Cancer
|
nivolumab + ramucirumab Sensitive: C3 – Early Trials
|
nivolumab + ramucirumab Sensitive: C3 – Early Trials
|
IL6 elevation
|
NSCLC
|
IL6 elevation
|
NSCLC
|
ABBV-181 Sensitive: C3 – Early Trials
|
ABBV-181 Sensitive: C3 – Early Trials
|
IL6 elevation
|
Cervical Cancer
|
IL6 elevation
|
Cervical Cancer
|
ipilimumab Resistant: C3 – Early Trials
|
ipilimumab Resistant: C3 – Early Trials
|
IL6 elevation
|
Melanoma
|
IL6 elevation
|
Melanoma
|
nivolumab Resistant: C3 – Early Trials
|
nivolumab Resistant: C3 – Early Trials
|
IL6 elevation
|
Small Cell Lung Cancer
|
IL6 elevation
|
Small Cell Lung Cancer
|
ipilimumab Resistant: C3 – Early Trials
|
ipilimumab Resistant: C3 – Early Trials
|
IL6 elevation
|
Uveal Melanoma
|
IL6 elevation
|
Uveal Melanoma
|
tebentafusp Sensitive: C3 – Early Trials
|
tebentafusp Sensitive: C3 – Early Trials
|
IL6 elevation
|
Clear Cell Renal Cell Carcinoma
|
IL6 elevation
|
Clear Cell Renal Cell Carcinoma
|
nivolumab Resistant: C3 – Early Trials
|
nivolumab Resistant: C3 – Early Trials
|
IL6 elevation
|
HCC
|
IL6 elevation
|
HCC
|
bevacizumab + atezolizumab Resistant: C3 – Early Trials
|
bevacizumab + atezolizumab Resistant: C3 – Early Trials
|
IL6 elevation
|
Diffuse Large B Cell Lymphoma
|
IL6 elevation
|
Diffuse Large B Cell Lymphoma
|
axicabtagene ciloleucel Resistant: C3 – Early Trials
|
axicabtagene ciloleucel Resistant: C3 – Early Trials
|
IL6 elevation
|
Mantle Cell Lymphoma
|
IL6 elevation
|
Mantle Cell Lymphoma
|
TG-1701 Sensitive: D – Preclinical
|
TG-1701 Sensitive: D – Preclinical
|
IL6 elevation
|
Mantle Cell Lymphoma
|
IL6 elevation
|
Mantle Cell Lymphoma
|
umbralisib + TG-1701 + ublituximab Sensitive: D – Preclinical
|
umbralisib + TG-1701 + ublituximab Sensitive: D – Preclinical
|